Being heard on all-oral therapy for resistant TB

A study, published in The Lancet Infectious Diseases, compared outcomes up to 24 months after treatment initiation for patients with rifampicin-resistant TB in South Africa treated with a short, all-oral bedaquiline-containing regimen, or a short, injectable-containing regimen.

An accompanying comment can be accessed here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Norbert Ndjeka et al.

Published: June 22, 2022, 10:49 p.m.

Last updated: June 23, 2022, 11:52 p.m.

Print Share